SI3481859T1 - Topni polipeptidi receptorja 3 fibroblastnega rastnega faktorja (SFGFR3) in njihove uporabe - Google Patents

Topni polipeptidi receptorja 3 fibroblastnega rastnega faktorja (SFGFR3) in njihove uporabe

Info

Publication number
SI3481859T1
SI3481859T1 SI201731158T SI201731158T SI3481859T1 SI 3481859 T1 SI3481859 T1 SI 3481859T1 SI 201731158 T SI201731158 T SI 201731158T SI 201731158 T SI201731158 T SI 201731158T SI 3481859 T1 SI3481859 T1 SI 3481859T1
Authority
SI
Slovenia
Prior art keywords
sfgfr3
polypeptides
growth factor
factor receptor
fibroblast growth
Prior art date
Application number
SI201731158T
Other languages
English (en)
Slovenian (sl)
Inventor
Elvire Gouze
Stephanie Garcia
Original Assignee
Inserm (Institut National De La Sante Et De La Recherche Medicale)
Pfizer Inc.
Universite Cote d'Azur Grand Chateau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inserm (Institut National De La Sante Et De La Recherche Medicale), Pfizer Inc., Universite Cote d'Azur Grand Chateau filed Critical Inserm (Institut National De La Sante Et De La Recherche Medicale)
Publication of SI3481859T1 publication Critical patent/SI3481859T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SI201731158T 2016-07-07 2017-07-07 Topni polipeptidi receptorja 3 fibroblastnega rastnega faktorja (SFGFR3) in njihove uporabe SI3481859T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662359607P 2016-07-07 2016-07-07
US201762467478P 2017-03-06 2017-03-06
EP17742195.5A EP3481859B1 (en) 2016-07-07 2017-07-07 Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof
PCT/EP2017/067119 WO2018007597A1 (en) 2016-07-07 2017-07-07 Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
SI3481859T1 true SI3481859T1 (sl) 2022-07-29

Family

ID=59381265

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201731158T SI3481859T1 (sl) 2016-07-07 2017-07-07 Topni polipeptidi receptorja 3 fibroblastnega rastnega faktorja (SFGFR3) in njihove uporabe

Country Status (20)

Country Link
US (3) US10294289B2 (enExample)
EP (2) EP4122955A1 (enExample)
JP (2) JP7046903B2 (enExample)
KR (2) KR102432192B1 (enExample)
CN (1) CN109715658B (enExample)
AU (2) AU2017294551B2 (enExample)
BR (1) BR112019000257A2 (enExample)
CA (1) CA3029877C (enExample)
DK (1) DK3481859T3 (enExample)
ES (1) ES2912559T3 (enExample)
HU (1) HUE058734T2 (enExample)
IL (1) IL264030A (enExample)
MX (1) MX2018016257A (enExample)
PL (1) PL3481859T3 (enExample)
PT (1) PT3481859T (enExample)
RU (1) RU2751483C2 (enExample)
SG (1) SG11201900074WA (enExample)
SI (1) SI3481859T1 (enExample)
WO (1) WO2018007597A1 (enExample)
ZA (1) ZA201900507B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201591324A1 (ru) 2013-01-16 2016-01-29 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
RU2751483C2 (ru) 2016-07-07 2021-07-14 Пфайзер Инк. Полипептиды, являющиеся растворимыми рецепторами 3 фактора роста фибробластов (sfgfr3), и пути их применения
CA3076396A1 (en) * 2017-09-20 2019-03-28 Pfizer Inc. Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides
WO2020243478A1 (en) * 2019-05-29 2020-12-03 Massachusetts Eye And Ear Infirmary Fibroblast growth factor 2 (fgf2) for treatment of human sensorineural hearing loss
US11625937B2 (en) * 2020-04-06 2023-04-11 Toyota Motor Engineering & Manufacturing North America, Inc. Methods and systems for monitoring human body weight with vehicle sensors and big data AI analytics
WO2022106976A1 (en) 2020-11-18 2022-05-27 Pfizer Inc. Stable pharmaceutical formulations of soluble fgfr3 decoys
WO2022254319A1 (en) 2021-06-01 2022-12-08 Pfizer Inc. Cell culture method for producing sfgfr3 polypeptide
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
WO2024194300A1 (en) 2023-03-20 2024-09-26 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
CN116284327A (zh) * 2023-03-28 2023-06-23 中国药科大学 一种靶向肿瘤的成纤维细胞生长因子19的重组蛋白及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
DK0833620T3 (da) 1995-06-12 2003-01-13 Yeda Res & Dev FGFR3, en markør for mesenkymale progenitorceller
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US20040109850A1 (en) 2000-12-18 2004-06-10 Neelam Jaiswal Treatment of bone disorders by modulation of fgfr3
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
JP2003104908A (ja) 2001-09-28 2003-04-09 Ichikazu Nakao 軟骨無形成症治療剤
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
ATE533853T1 (de) 2004-02-24 2011-12-15 Allergan Inc Botulinumtoxin-screening-assays
EP2083081A1 (en) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
CA2655504A1 (en) 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
EP2083846B1 (en) 2006-09-28 2015-07-15 Hepacore Ltd. N-terminal fgf variants having increased receptor selectivity and uses thereof
WO2008133873A2 (en) 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
US8426396B2 (en) 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
WO2010002862A2 (en) 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
RU2509774C2 (ru) 2008-08-04 2014-03-20 Файв Прайм Терапьютикс, Инк. Мутеины кислотной зоны внеклеточного домена рецептора фактора роста фибробластов
TWI381848B (zh) 2008-10-20 2013-01-11 Imclone Llc 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物
AU2010229994B2 (en) 2009-03-25 2016-08-18 Genentech, Inc. Anti-FGFR3 antibodies and methods using same
EP2478003A4 (en) 2009-09-15 2013-05-29 Five Prime Therapeutics Inc HAIR GROWTH METHODS USING THE EXTRACELLULAR DOMAINS OF FGFR4
US8614183B2 (en) 2009-11-13 2013-12-24 Five Prime Therapeutics, Inc. Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2
EP2512501A4 (en) 2009-12-17 2014-01-01 Five Prime Therapeutics Inc METHODS FOR PROMOTING HAIR GROWTH USING FGFR3 EXTRACELLULAR DOMAINS
WO2011088196A2 (en) 2010-01-14 2011-07-21 Yale University Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
CN102219860B (zh) 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
EA030440B1 (ru) 2011-10-24 2018-08-31 Галозим, Инк. Сопровождающая диагностика для терапии антигиалуронановым агентом и способы ее применения
FR2984325A1 (fr) 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
AU2013295805B2 (en) 2012-07-24 2019-05-02 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
KR20150037876A (ko) 2012-07-27 2015-04-08 제넨테크, 인크. Fgfr3 관련 상태의 치료 방법
EP4223770A3 (en) 2012-11-05 2023-10-18 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
EA201591324A1 (ru) * 2013-01-16 2016-01-29 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
NZ722377A (en) 2014-01-24 2022-09-30 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
EP3242888B8 (en) * 2015-01-07 2021-06-02 Pfizer Inc. Soluble fgfr3 decoys for treating skeletal growth disorders
RU2751483C2 (ru) 2016-07-07 2021-07-14 Пфайзер Инк. Полипептиды, являющиеся растворимыми рецепторами 3 фактора роста фибробластов (sfgfr3), и пути их применения
CA3076396A1 (en) 2017-09-20 2019-03-28 Pfizer Inc. Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides

Also Published As

Publication number Publication date
CN109715658B (zh) 2023-09-12
BR112019000257A2 (pt) 2019-10-01
WO2018007597A1 (en) 2018-01-11
CA3029877A1 (en) 2018-01-11
US20200190162A1 (en) 2020-06-18
RU2019100381A (ru) 2020-08-11
CA3029877C (en) 2023-07-25
KR20190037240A (ko) 2019-04-05
ZA201900507B (en) 2023-04-26
US10294289B2 (en) 2019-05-21
EP3481859A1 (en) 2019-05-15
JP2019527053A (ja) 2019-09-26
US20180230197A1 (en) 2018-08-16
AU2017294551A1 (en) 2019-01-31
US20210309718A1 (en) 2021-10-07
PL3481859T3 (pl) 2022-07-11
KR20220122762A (ko) 2022-09-02
SG11201900074WA (en) 2019-02-27
EP3481859B1 (en) 2022-04-13
KR102432192B1 (ko) 2022-08-12
MX2018016257A (es) 2019-11-21
RU2751483C2 (ru) 2021-07-14
EP4122955A1 (en) 2023-01-25
IL264030A (en) 2019-01-31
JP7348980B2 (ja) 2023-09-21
RU2019100381A3 (enExample) 2020-11-23
ES2912559T3 (es) 2022-05-26
US11021528B2 (en) 2021-06-01
AU2017294551B2 (en) 2022-03-03
PT3481859T (pt) 2022-05-23
US11697678B2 (en) 2023-07-11
JP2022096660A (ja) 2022-06-29
AU2022202906A1 (en) 2022-05-26
CN109715658A (zh) 2019-05-03
DK3481859T3 (da) 2022-04-25
HUE058734T2 (hu) 2022-09-28
JP7046903B2 (ja) 2022-04-04

Similar Documents

Publication Publication Date Title
ZA201900507B (en) Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof
IL273327A (en) Chimeric polypeptides and their uses
IL281273A (en) Adapted 21–FGF polypeptides and their uses
IL275463A (en) TLR7/8 antagonists and their use
SG11202006420TA (en) Transferrin receptor-binding polypeptides and uses thereof
IL292692A (en) mrgprx2 antagonists and their uses
IL273253A (en) Glucagon-like peptide-1 receptor agonists and their uses
IL287781A (en) Clec-12a binding polypeptides and uses thereof
IL280808A (en) OX40-binding polypeptides and their uses
IL272749A (en) Soluble interferon receptors and their uses
SMT202300299T1 (it) Nuovi polipeptidi e relativi usi medici
GB2603645B (en) Polypeptides having anti-senescent effects and uses thereof
IL292693A (en) mrgprx2 antagonists and their uses
IL287782A (en) 33cd-binding polypeptides and their uses
EP3813861A4 (en) HEPARIN-ASSOCIATED POLYPEPTIDES AND THEIR USES
IL274751A (en) ILDR2 antagonists and combinations thereof
SG11201912799SA (en) Recombinant human-basic fibroblast growth factor (rh-bfgf) and pharmaceutical composition comprising rh-bfgf
GB201819200D0 (en) Polypeptide and uses thereof
GB201707139D0 (en) Polypeptides
GB201812328D0 (en) Polypeptides and uses thereof
GB201712266D0 (en) polypeptides and uses thereof
GB201712268D0 (en) Polypeptides and uses thereof
HK40031554A (en) Soluble interferon receptors and uses thereof
HK40023936A (en) Glucagon-like peptide 1 receptor agonists and uses thereof
HK40050222A (en) Ox40-binding polypeptides and uses thereof